

NCT02888704 Raw comparison:

Summary:
CHIA has 17 criteria while your personal folder has 19 criteria
Total found criteria: 17/17
Total not Found: 0/17
Total Extra: 2
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ Of either gender aged ≥19 and ≤70 years            │ Of either gender aged ≥19 and ≤70 years            │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Atopic dermatitis subjects who are coincident with │ Atopic dermatitis subjects who are coincident with │
│ Hanifin and Rajka diagnosis criteria               │ Hanifin and Rajka diagnosis criteria               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subacute and chronic atopic subjects who have      │ Subacute and chronic atopic subjects who have      │
│ atopic dermatitis symptoms continually at least 6  │ atopic dermatitis symptoms continually at least 6  │
│ months                                             │ months                                             │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects with over moderate atopic dermatitis      │ Subjects with over moderate atopic dermatitis      │
│ (SCORAD score > 20)                                │ (SCORAD score \> 20)                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects who understand and voluntarily sign an    │ Subjects who understand and voluntarily sign an    │
│ informed consent form                              │ informed consent form                              │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects who have systemic infection               │ Subjects who have systemic infection               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects who have human Immunodeficiency virus     │ Subjects who have human Immunodeficiency virus     │
│ (HIV) hepatitis B virus (HBV) and hepatitis C      │ (HIV) hepatitis B virus (HBV) and hepatitis C      │
│ virus (HCV)                                        │ virus (HCV)                                        │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects who need to take the medicine which is    │ Subjects who need to take the medicine which is    │
│ prohibited during this study                       │ prohibited during this study                       │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects who have asthma                           │ Subjects who have asthma                           │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects who can not stop treatment with topical   │ Subjects who can not stop treatment with topical   │
│ steroids (group 1~5) oral antibiotics whole body   │ steroids (group 1\~5) oral antibiotics whole body  │
│ photochemotherapy immunosuppressive drug within 4  │ photochemotherapy immunosuppressive drug within 4  │
│ weeks before the treatment visit                   │ weeks before the treatment visit                   │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Pregnant breast-feeding women or women who plan to │ Pregnant breast-feeding women or women who plan to │
│ become pregnant during this study (Females of      │ become pregnant during this study (Females of      │
│ childbearing potential must have a negative urine  │ childbearing potential must have a negative urine  │
│ pregnancy test)                                    │ pregnancy test)                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects who currently participate in other        │ Subjects who currently participate in other        │
│ clinical trial or participated in other clinical   │ clinical trial or participated in other clinical   │
│ trial within 30 days                               │ trial within 30 days                               │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects who had a serious adverse events during   │ Subjects who had a serious adverse events during   │
│ stem cell therapy                                  │ stem cell therapy                                  │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects who had a hypersensitivity to antibiotics │ Subjects who had a hypersensitivity to antibiotics │
│ or antimycotics                                    │ or antimycotics                                    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects who creatinine value is more than two     │ Subjects who creatinine value is more than two     │
│ times of the upper limit of the normal range at    │ times of the upper limit of the normal range at    │
│ screening test                                     │ screening test                                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects who aspartate transaminase/alkaline       │ Subjects who aspartate transaminase/alkaline       │
│ transaminase (AST/ALT) value is more than three    │ transaminase (AST/ALT) value is more than three    │
│ times of the upper limit of the normal range at    │ times of the upper limit of the normal range at    │
│ screening test                                     │ screening test                                     │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ Subjects who have any other condition which the    │ Subjects who have any other condition which the    │
│ investigator judges would make patients unsuitable │ investigator judges would make patients unsuitable │
│ for study participation                            │ for study participation                            │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒═══════════════════════════════════╕
│ Extra Personal Criteria           │
╞═══════════════════════════════════╡
│ Must have maximum age of 70 Years │
├───────────────────────────────────┤
│ Must have minimum age of 19 Years │
╘═══════════════════════════════════╛